Exploring the content and psychometric validity of clinical outcome assessments in pancreatic ductal adenocarcinoma versus the patient reported symptoms and impacts

Presented at ISPOR 2024

I Petit¹, B Romero², L Eliasson³, C Patel³, J Quinn¹

¹Debiopharm SA, Switzerland
²Sprout Health Solutions Limited, US
³Sprout Health Solutions Limited, UK